Insulin prices have sparked outrage in recent months, with Congress holding hearings on the issue and launching bipartisan investigations into why the cost of the hormone used to treat diabetes – discovered nearly a century ago – has soared over the past two decades. The House Energy and Commerce oversight subcommittee held a hearing on insulin prices this week and will hold another next week. Executives from the three companies that dominate the global insulin market – Eli Lilly, Novo Nordisk and Sanofi – are expected to testify at the upcoming hearing. “We want to know why the cost of this life-saving drug has skyrocketed in recent years, and why they’re not offering more lower-cost alternatives to patients,” Rep. Diana DeGette (D-CO), who chairs the subcommittee, said this week.
Source: Soaring insulin prices in the US are costing Medicare billions